Objectives: The adhesion molecule L-selectin plays an important role in leu
kocyte-endothelium interactions, thereby contributing to inflammatory react
ions. We tested the hypothesis that humanized anti-L-selectin antibodies re
duce trauma-associated organ damage and mortality.
Design: Prospective, randomized experimental study.
Setting: Independent nonprofit research laboratory in a trauma hospital (Lu
dwig Boltzmann Institute) and a contract research institute (Biocon),
Subjects: Twenty-eight male baboons (Papio ursinus), 18 to 29 kg,
Interventions: Hemorrhagic-traumatic shock was created by complement activa
tion with cobra venom factor, followed by withdrawal of blood to a mean art
erial pressure of 35 to 45 mm Hg, Blood and lactated Ringer's solution were
reinfused. Animals were randomized to receive either 2 mg/kg humanized ant
i-L selectin antibody (HuDREG-55 [Ab]) or placebo (lactated Ringer's soluti
on [LRS]),
Measurements and Main Results: Treatment with humanized anti-L-selectin ant
ibody decreased mortality (Ab 21% vs. LRS 71%; p = .011) and improved survi
val time (p = .016), A trend toward reduced organ damage, especially in the
adrenal glands (score 1.2 +/- 0.2 placebo vs, 1.0 +/- 0.1 antibody; p = .0
59) was seen, and at 24 hrs was accompanied by significantly increased mean
arterial pressure (Ab 99 +/- 6 mm Hg vs. LRS 79 +/- 8 mm Hg; p = .023), ca
rdiac output (Ab 3.4 +/- 0.2 L/min vs. LRS 2.4 +/- 0.3 L/min; p = .007), co
re temperature (p = .048), and improved perfusion, with less negative base
excess (Ab 2.9 +/- 1.1 vs. LRS 2.1 +/- 1.7; p = .019) and a trend toward le
ss lactate (p = .065), These improvements were accompanied by significantly
(p = .008) decreased fluid requirements in the treatment group (Ab 11.7 +/
- 2.5 mL/kg/hr vs. LRS 23.0 +/- 2.3 mL/kg/hr), There were also fewer circul
ating leukocytes (p = .042) in the treatment group at 24 hrs.
Conclusion: Humanized anti-L-selectin antibody has beneficial effects on su
rvival in a long-term in vivo model of hemorrhagic-traumatic shock.